In the recent past most pharmaceutical companies had a large number of factories scattered all over the world.

More recently, production plants have been significantly reorganised and concentrated as the result of:

  • Increased pressure on costs
  • Governments may be less able to subsidise investments of mid-size companies
  • Merger / acquisition activities
  • New, strict GMP rules
  • Focus on other core activities (Business Development e Production)

Consequently, pharmaceutical companies are concentrating their manufacturing efforts on their core products and new technologies Major opportunities are being offered for the outsourcing of:

  • Classical Manufacturing
  • High Class Generics (2010)
  • Generics / Supergenerics Production
  • Niches where heavy capital investment can be avoided
  • Third-party manufacturers will be successful when located in countries where outstanding pharmaceutical skills are available together with flexibility, creativity and a customer-oriented service culture. Northern Italy fits this picture perfectly.


Focus on Technology / Innovation


  • State-of-the-art site
  • FDA approval
  • Special production
  • New technical strategy (Lean + IQP)

Development / Special Services

  • Using new technological platforms
  • Supergenerics

For any information you can contact our staff calling us, sending us an email or using the form in the Contact page.